Study guide
7.4 Neuromuscular Disorders & Movement Disorders
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
7.4 Neuromuscular Disorders & Movement Disorders
Key Takeaways Explain This Topic AI
Peripheral neuropathies present with symmetrical distal 'glove-and-stocking' sensory loss; vitamin B12 deficiency produces subacute combined degeneration of the cord combining dorsal column sensory ataxia with lateral corticospinal tract upper motor neuron weakness and absent ankle reflexes.
Guillain-Barré syndrome is an acute post-infectious demyelinating polyneuropathy (commonly post-Campylobacter jejuni) presenting with ascending flaccid weakness, areflexia, and autonomic instability; serial forced vital capacity (FVC) monitoring is critical, and treatment is IVIG or plasma exchange (corticosteroids are ineffective).
Myasthenia gravis is an autoimmune postsynaptic NMJ disorder with anti-AChR or anti-MuSK antibodies causing fatigable ocular, bulbar, and proximal weakness with preserved reflexes; patients require CT chest to screen for thymoma, treatment with pyridostigmine, and strict avoidance of aminoglycosides, beta-blockers, and macrolides.
Parkinson's disease presents with an asymmetrical resting tremor (4–6 Hz), lead-pipe/cogwheel rigidity, and bradykinesia; levodopa is first-line when quality of life is impaired, while dopamine agonists carry a high risk of impulse control disorders (gambling, hypersexuality).
Multiple sclerosis relapses are treated acutely with high-dose methylprednisolone (oral 500 mg daily for 5 days or IV 1 g daily for 3–5 days); clinical markers include optic neuritis with relative afferent pupillary defect, Uhthoff's phenomenon, and CSF oligoclonal bands.
Last updated: October 2026
Neuromuscular Disorders & Movement Disorders
Neuromuscular disorders encompass pathological lesions extending from the anterior horn cell and peripheral nerve to the neuromuscular junction and muscle fibre. Recognizing anatomical localization and identifying early signs of respiratory muscle compromise are paramount in emergency neurological care.
- Peripheral Neuropathies & Subacute Combined Degeneration
- 1. Symmetrical Distal Polyneuropathy
Clinical Presentation: Length-dependent axonal loss or demyelination producing symmetrical 'glove-and-stocking' sensory impairment (loss of vibration, proprioception, pinprick, and temperature starting in toes and feet, ascending to mid-shin before involving fingertips), distal lower limb muscle wasting, and loss of the ankle jerk reflexes.
Common Aetiologies: Diabetic polyneuropathy (most common overall), chronic alcohol excess, chronic kidney disease (uraemic neuropathy), chemotherapy agents (vincristine, cisplatin, taxanes), and paraproteinaemias.
Diabetic Neuropathy Management: Strict glycaemic optimization, annual podiatric diabetic foot screening, and first-line pharmacological treatment for neuropathic pain using Duloxetine (60 mg daily), Amitriptyline (10–75 mg nocte), Gabapentin , or Pregabalin .
2. Subacute Combined Degeneration of the Spinal Cord (SCDSC)
Pathophysiology: Caused by severe Vitamin B12 (Cobalamin) deficiency (commonly pernicious anaemia or ileal resection), leading to defective myelin synthesis affecting both the central and peripheral nervous systems.
Anatomical Pathways Affected:
Dorsal Columns: Bilateral loss of vibration and joint position sense, sensory ataxia, positive Romberg's sign, and pseudoathetosis.
Lateral Corticospinal Tracts: Upper motor neuron signs: spastic paraparesis, hypertonia, and bilateral extensor plantar responses (positive Babinski sign).
Peripheral Nerves: Symmetrical distal sensory loss and hyporeflexia.
Classic Exam Paradox: Bilateral extensor plantars (UMN) combined with absent ankle jerks (LMN) .
Investigations: Low serum B12 (<150 ng/L), macrocytic anaemia with elevated mean corpuscular volume (MCV > 100 fL), hypersegmented neutrophils on blood film, anti-intrinsic factor antibodies.
Critical Prescribing Rule: Always replace Vitamin B12 (intramuscular Hydroxocobalamin) before or concurrently with Folic acid. Treating B12 deficiency with folic acid alone corrects megaloblastic anaemia while catastrophically accelerating irreversible subacute combined degeneration of the spinal cord.
Guillain-Barré Syndrome vs. Myasthenia Gravis
Rapid differentiation between Guillain-Barré syndrome (GBS) and Myasthenia Gravis (MG) is a high-yield clinical competence, as both can cause acute neuromuscular respiratory failure.
Clinical Feature Guillain-Barré Syndrome (GBS / AIDP) Myasthenia Gravis (MG)
Primary Pathophysiology Acute post-infectious demyelination of peripheral nerves and roots driven by molecular mimicry Autoimmune destruction of post-synaptic nicotinic acetylcholine receptors (AChR) or MuSK at the NMJ
Precipitating Triggers Preceding gastroenteritis ( Campylobacter jejuni #1) or upper respiratory infection (CMV, EBV, Zika) 1–3 weeks prior Pregnancy, systemic infection, emotional stress, surgery, or culprit medications (aminoglycosides, beta-blockers)
Pattern of Weakness Symmetrical, rapidly progressive ascending flaccid paralysis (starts in legs, ascends to arms, trunk, and cranial nerves) Fatigable muscle weakness (worsens with repetitive exertion and towards evening; improves with rest); extraocular and bulbar predilection
Deep Tendon Reflexes Generalised Areflexia / Hyporeflexia (early, universal finding) Preserved / Normal reflexes (never depressed by the disease)
Cranial Nerve Involvement Bilateral Lower Motor Neuron Facial Nerve (CN VII) palsy in ~50% of cases Extraocular muscles (asymmetric ptosis, diplopia with pupillary sparing); bulbar weakness (dysphagia, nasal dysarthria)
Sensory Findings Distal mild paresthesias or sensory loss common; severe back/radicular pain Completely absent (pure motor disorder; sensation is always intact)
Autonomic Dysfunction Frequent and life-threatening: labile blood pressure, cardiac arrhythmias, sinus tachycardia, urinary retention Absent / rare
CSF Findings Albuminocytological Dissociation: Markedly elevated protein (>0.55–2.0 g/L) with normal white cell count (<5/µL) Completely normal CSF composition
Bedside & Confirmatory Tests Serial Forced Vital Capacity (FVC) every 4–6h; demyelinating conduction block on nerve conduction studies Ice pack test (>2 mm ptosis improvement after 2–5 min); serum anti-AChR / anti-MuSK antibodies; single-fibre EMG (increased jitter)
Thymic Association None Thymoma present in 10–15% ; thymic lymphoid hyperplasia in 65%; mandatory CT thorax screening in all patients
Definitive Treatment IV Immunoglobulin (IVIG 0.4 g/kg/day for 5 days) OR Plasma Exchange (Plasmapheresis) First-line symptomatic: Oral Pyridostigmine (acetylcholinesterase inhibitor); Immunosuppression: Prednisolone + Azathioprine
Role of Corticosteroids Corticosteroids are INEFFECTIVE and NOT recommended (clinical trials show no benefit and potential harm) Standard second-line disease-modifying therapy (titrated carefully to avoid initial steroid-induced flare)
Acute Respiratory Failure & Crisis Management
Forced Vital Capacity (FVC) Monitoring: The gold standard bedside assessment in both GBS and Myasthenic Crisis. Peak expiratory flow rate (PEFR) is unreliable because it reflects airway caliber rather than diaphragmatic neuromuscular strength. FVC must be checked every 4–6 hours.
Indications for Urgent ICU Admission & Elective Endotracheal Intubation:
- FVC falling below 15–20 mL/kg (or <1.0 L in an average adult)
- Maximum inspiratory pressure < 30 cm H₂O
Paradoxical abdominal breathing (inward movement of abdomen on inspiration indicating diaphragmatic exhaustion)
- Single-breath counting < 15
- Arterial blood gas showing hypercapnic respiratory acidosis (late, catastrophic sign)
Drugs to Strictly Avoid in Myasthenia Gravis:
Antibiotics: Aminoglycosides (gentamicin, amikacin), Macrolides (clarithromycin, erythromycin), Fluoroquinolones (ciprofloxacin)
- Cardiovascular: Beta-blockers (propranolol, atenolol), Calcium channel blockers
- Other: Magnesium sulphate, D-penicillamine, neuromuscular blocking drugs (vecuronium, rocuronium)
- Parkinson's Disease & Movement Disorders
Parkinson's disease is a progressive neurodegenerative disorder caused by degeneration of dopaminergic neurons within the substantia nigra pars compacta , resulting in striatal dopamine depletion. Histopathology reveals intracytoplasmic Lewy bodies composed of aggregated alpha-synuclein .
The Cardinal Motor Triad (Characteristically Asymmetric Onset)
Resting Tremor: 4–6 Hz coarse tremor, classically 'pill-rolling' (thumb rubbing against index finger). Present at rest, dampened during voluntary purposeful movement, and exaggerated by distraction or mental stress.
Rigidity: Increased tone sustained throughout the entire passive range of motion. Appears as lead-pipe rigidity (smooth uniform resistance) or cogwheel rigidity (ratchet-like resistance produced by underlying resting tremor superimposed on lead-pipe rigidity).
Bradykinesia: Slowness of movement initiation and progressive decrement in amplitude and speed during repetitive movements (tested via finger tapping or foot tapping). Manifests clinically as hypomimia ('masked' facial expression), reduced blink rate, micrographia (handwriting becoming progressively smaller and cramped), quiet/monotone hypophonic speech, and a slow, shuffling festinant gait with reduced unilateral arm swing and difficulty turning ('en bloc').
Non-Motor Features: Often predate motor signs by years: anosmia (loss of smell), REM sleep behaviour disorder (vocalizing or acting out dreams), chronic constipation, orthostatic hypotension, depression, and late-stage Lewy body dementia.
Pharmacotherapy of Parkinson's Disease (NICE Guidelines)
Pharmacological Class Representative Agents Mechanism of Action Clinical Role & Indications Key Adverse Effects & Clinical Pearls
Dopamine Precursor + Peripheral DDC Inhibitor Co-beneldopa (Levodopa + Benserazide); Co-careldopa (Levodopa + Carbidopa) Levodopa crosses the blood-brain barrier and is converted to dopamine; DDC inhibitor prevents peripheral breakdown Most effective symptomatic therapy. First-line when motor symptoms impair quality of life Nausea, orthostatic hypotension, visual hallucinations. Long-term use (>5 years) leads to motor complications: 'wearing-off' (end-of-dose motor fluctuations) and peak-dose dyskinesias (chorea/dystonia)
Non-Ergot Dopamine Agonists Pramipexole , Ropinirole , Rotigotine (transdermal patch) Direct stimulation of post-synaptic striatal D₂ and D₃ dopamine receptors Initial monotherapy in younger patients (<60–65y) to delay levodopa-associated motor complications Impulse Control Disorders (ICDs) in up to 15% (pathological gambling, hypersexuality, binge eating, compulsive spending); excessive daytime somnolence and sudden-onset sleep attacks
MAO-B Inhibitors Rasagiline , Selegiline Irreversibly inhibit monoamine oxidase B, preventing central dopamine catabolism Initial monotherapy for mild motor symptoms or adjunct to reduce levodopa motor fluctuations Insomnia, headache; do not provoke the 'cheese reaction' at clinical doses due to MAO-B selectivity
COMT Inhibitors Entacapone , Tolcapone Inhibit catechol-O-methyltransferase, preventing peripheral metabolism of levodopa Strictly adjunctive therapy with levodopa to extend its half-life and reduce 'wearing-off' Exacerbates levodopa dyskinesias; harmless reddish-brown/orange discoloration of urine (entacapone); hepatotoxicity requiring regular LFTs (tolcapone)
Ergot Dopamine Agonists Bromocriptine, Cabergoline Direct dopamine receptor stimulation Rarely used; strictly restricted due to fibrotic complications Cardiac valvular fibrosis, pulmonary fibrosis, retroperitoneal fibrosis ; requires baseline echocardiogram, CXR, and ESR
Atypical Parkinsonian Syndromes (Parkinson-Plus)
Progressive Supranuclear Palsy (PSP): Characterised by symmetrical onset, early unexplained postural instability and falls within the first 12 months, supranuclear vertical gaze palsy (marked limitation of downward voluntary saccades), axial rigidity greater than limb rigidity, retrocollis, and poor response to levodopa.
Multiple System Atrophy (MSA): Characterised by parkinsonian features combined with severe, early autonomic failure (profound orthostatic hypotension, urinary incontinence, erectile dysfunction) and/or cerebellar ataxia (MSA-C). MRI may show the 'hot cross bun' sign in the pons.
Multiple Sclerosis (MS)
Multiple Sclerosis is a chronic autoimmune inflammatory demyelinating disease of the central nervous system disseminated in space (multiple anatomical CNS lesions) and time (multiple episodes separated by time).
Subtypes: Relapsing-Remitting MS (RRMS; ~85% of initial presentations), Secondary Progressive MS (SPMS), and Primary Progressive MS (PPMS; progressive from onset).
Characteristic Manifestations:
Optic Neuritis: Subacute painful unilateral visual loss, central scotoma, marked colour desaturation (especially red desaturation ), and a Relative Afferent Pupillary Defect (RAPD / Marcus Gunn pupil).
Uhthoff's Phenomenon: Transient worsening of existing neurological symptoms triggered by elevated body temperature (hot bath, intense physical exercise, or fever).
Lhermitte's Sign: Electric shock-like sensation shooting down the spine into the limbs provoked by forward neck flexion (indicating cervical cord demyelinating plaques).
Internuclear Ophthalmoplegia (INO): Demyelination of the medial longitudinal fasciculus (MLF); failure of adduction in the ipsilateral eye with horizontal nystagmus of the contralateral abducting eye on lateral conjugate gaze.
Diagnostic Investigations:
MRI Brain and Spine with Gadolinium: Demonstrates periventricular demyelinating plaques oriented perpendicular to the lateral ventricles ( 'Dawson's fingers' ), infratentorial, and spinal lesions.
Lumbar Puncture: Demonstrates oligoclonal IgG bands present in the CSF that are absent in matched serum (reflecting intrathecal clonal B-cell immunoglobulin synthesis).
Relapse Management: Treat acute, disabling relapses with high-dose corticosteroid therapy to hasten clinical recovery: Oral Methylprednisolone 500 mg daily for 5 days OR Intravenous Methylprednisolone 1 g daily for 3–5 days . (Note: Steroids accelerate relapse recovery but do not alter long-term disease progression).
Essential Tremor
The commonest movement disorder: a bilateral postural and action tremor of the hands (and sometimes head or voice), often with a family history (autosomal dominant) and temporary improvement with alcohol . Unlike Parkinson's disease there is no rigidity or bradykinesia and the tremor is absent at rest. Treatment, if it interferes with function, is propranolol or primidone .